189442-92-0

Basic information

• Product Name: 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE
• Synonyms: 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE;2-Methyl-2-Propanyl 4-ForMyl-4-Methyl-1-Piperidinecarboxylate;1-tert-Butoxycarbonyl-4-methylpiperidine-4-carboxaldehyde;4-Formyl-4-methylpiperidine-1-carboxylic acid;tert-Butyl 4-formyl-4-methylpiperidine-1-carboxylate
• CAS NO: 189442-92-0
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.3
• Mol File: 189442-92-0.mol

Chemical Properties

• Boiling Point: 300.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.083±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -2.10±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE(189442-92-0)
• EPA Substance Registry System: 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE(189442-92-0)

Safety Data

• Hazardous Substances Data: 189442-92-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-BOC-4-FORMYL-4-METHYL-PIPERIDINE is used as a key intermediate in the synthesis of various drug candidates for the treatment of different diseases. Its unique structure allows for the attachment of different functional groups, enabling the creation of diverse molecules with potential therapeutic properties.
Used in Chemical Research:
In the field of chemical research, 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE is utilized as a building block for the development of novel compounds with specific chemical properties. Its presence of a BOC protecting group and functional groups on the piperidine ring makes it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
1-BOC-4-FORMYL-4-METHYL-PIPERIDINE is employed as a structural component in the design of new pharmaceutical agents. Its ability to be modified and functionalized allows for the exploration of its potential in targeting specific biological pathways and receptors, contributing to the discovery of innovative treatments.
Used in Drug Development:
In the process of drug development, 1-BOC-4-FORMYL-4-METHYL-PIPERIDINE serves as a precursor in the synthesis of potential drug molecules. Its versatility in chemical reactions facilitates the generation of a wide range of compounds, which can be further optimized for improved pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Organic Synthesis:
1-BOC-4-FORMYL-4-METHYL-PIPERIDINE is utilized as a versatile starting material in organic synthesis, allowing for the construction of various complex organic molecules. Its presence of a BOC protecting group and functional groups on the piperidine ring provides opportunities for further chemical modifications, making it a valuable component in the synthesis of a broad array of organic compounds.

Upstream product

• 236406-21-6 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 74-88-4 methyl iodide 
• 189442-91-9 tert-butyl 4-[methoxy(methyl)carbamoyl]-4-methylpiperidine-1-carboxylate 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 724790-59-4 4-methyl-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 189321-63-9 1-(tert-butoxycarbonyl)-4-methylpiperidine-4-carboxylic acid 
• 189442-87-3 ethyl tert-butyl 4-methylpiperidine-1,4-dicarboxylate 

Downstream Products

• 236406-22-7 tert-butyl 4-(aminomethyl)-4-methylpiperidine-1-carboxylate 
• 189442-53-3 4-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 1567216-39-0 (S,E)-methyl 2-(2-(3-bromophenyl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate 
• 1567216-41-4 (2S)-2-(2-{3-[2-(but-3-en-1-yl)phenyl]phenyl}-7-{4-[(1E)-buta-1,3-dien-1-yl]-4-methylpiperidin-1-yl}-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate 
• 1567216-51-6 (S,E)-methyl 2-(7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-2-(5‘-chloro-2‘-hydroxy-[1,1‘-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate 
• 1567216-53-8 (S,E)-methyl 2-(2-(2’-(allyloxy)-5’-chloro-[1,1‘-biphenyl]-3-yl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate 

Relevant articles and documents

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

Discovery of conolidine derivative DS39201083 as a potent novel analgesic without mu opioid agonist activity

We discovered a novel compound, 5-methyl-1,4,5,7-tetrahydro-2,5-ethanoazocino[4,3-b]indol-6(3H)-one sulfuric acid salt (DS39201083), which was formed by derivatization of a natural product, conolidine. DS39201083 had a unique bicyclic skeleton and was a m

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compou

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compound